(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
Portfolio Pulse from Benzinga Insights
Biomarin Pharmaceutical's (NYSE:BMRN) short interest has increased by 20.25% since the last report, with 3.69 million shares sold short, representing 1.96% of its float. This indicates a bearish market sentiment, although it's below the peer group average of 5.96%. The article suggests that an increase in short interest doesn't necessarily predict a stock price fall.
May 09, 2024 | 5:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Biomarin Pharmaceutical's short interest has risen, indicating increased bearish sentiment, but remains below its peer average.
The increase in short interest suggests that investors are more bearish on BMRN, potentially leading to downward pressure on the stock price in the short term. However, being below the peer average might mitigate some negative perceptions.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 90